If the FDA and GlaxoSmithKline want to extricate themselves from their current public relations predicament surrounding the diabetes drug Avandia, they should put all the data that has been collected about the drug into the public domain.

FORBES: A Fix For The Avandia Mess

Initially, a court argued that Apotex's generic didn't run afoul of Glaxo's patents because some of the clinical trials done to test the drug essentially put it in the public domain.

FORBES: The Drug To Watch

Drug safety advocates and others have called for studies to be put in the public domain more quickly.

FORBES: Vytorin Study Shows No Benefit